MX2021013447A - Composiciones y procedimientos para el tratamiento de enfermedades oculares. - Google Patents

Composiciones y procedimientos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2021013447A
MX2021013447A MX2021013447A MX2021013447A MX2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A
Authority
MX
Mexico
Prior art keywords
compositions
methods
ocular diseases
treatment
disclosure relates
Prior art date
Application number
MX2021013447A
Other languages
English (en)
Inventor
Brenda K Mann
Hee - Kyoung Lee
Original Assignee
Eyegate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyegate Pharmaceuticals Inc filed Critical Eyegate Pharmaceuticals Inc
Publication of MX2021013447A publication Critical patent/MX2021013447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a composiciones y procedimientos para el tratamiento de enfermedades oculares con antibióticos. En particular, la divulgación se refiere a composiciones de hidrogel que contienen antibióticos y que no nublan la visión y que tienen un tiempo de contacto prolongado en el ojo y no interfieren con la cicatrización de heridas.
MX2021013447A 2019-05-03 2020-04-30 Composiciones y procedimientos para el tratamiento de enfermedades oculares. MX2021013447A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842995P 2019-05-03 2019-05-03
PCT/US2020/030691 WO2020227002A1 (en) 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2021013447A true MX2021013447A (es) 2022-02-11

Family

ID=70861542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013447A MX2021013447A (es) 2019-05-03 2020-04-30 Composiciones y procedimientos para el tratamiento de enfermedades oculares.

Country Status (9)

Country Link
US (2) US11376214B2 (es)
EP (1) EP3962452A1 (es)
JP (1) JP7334266B2 (es)
KR (2) KR20240038152A (es)
CN (1) CN114025742A (es)
CA (1) CA3139060A1 (es)
IL (1) IL287802B1 (es)
MX (1) MX2021013447A (es)
WO (1) WO2020227002A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10945858B2 (en) * 2010-09-03 2021-03-16 Globus Medical, Inc. Expandable interspinous process fixation device
GB202008857D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
GB202008853D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
CN112587475B (zh) * 2020-12-18 2022-09-13 华熙生物科技股份有限公司 一种载药凝胶及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2437417C (en) * 2001-02-22 2016-07-26 Anika Therapeutics, Inc. Thiol-modified hyaluronan
CA2703807C (en) * 2010-05-12 2017-10-24 Molly S. Shoichet Enhanced stability of inverse thermal gelling composite hydrogels
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US9782345B2 (en) * 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
US11440976B2 (en) 2017-09-01 2022-09-13 Pmidg, Llc Functionalized and crosslinked polymers
WO2019057035A1 (en) 2017-09-19 2019-03-28 The Hong Kong University Of Science And Technology BIOCOMPATIBLE MATERIAL AND METHODS OF MAKING AND USING THE SAME

Also Published As

Publication number Publication date
WO2020227002A1 (en) 2020-11-12
KR102649858B1 (ko) 2024-03-20
US20220287961A1 (en) 2022-09-15
IL287802A (en) 2022-01-01
US11376214B2 (en) 2022-07-05
JP7334266B2 (ja) 2023-08-28
KR20220004753A (ko) 2022-01-11
EP3962452A1 (en) 2022-03-09
JP2022530837A (ja) 2022-07-01
KR20240038152A (ko) 2024-03-22
CN114025742A (zh) 2022-02-08
US20200345634A1 (en) 2020-11-05
CA3139060A1 (en) 2020-11-12
IL287802B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
MX2021013447A (es) Composiciones y procedimientos para el tratamiento de enfermedades oculares.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
BR112018005318A2 (pt) ?polipeptídeos de lisina ativos contra bactérias gram-negativas?
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
AU2018236629A8 (en) Hydrogel patch
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2021002006A (es) Tratamiento del cancer de mama triple negativo con inhibicion dirigida del factor de crecimiento transformante beta (tgf-b).
JOP20200253A1 (ar) تركيبات وطرق لعلاج الحثل البقعي
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2018016003A (es) Tratamiento combinado para lesiones neurológicas.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
WO2020128070A3 (de) Kollagenhydrolysat zur verwendung gegen hautkrankheiten und darmkrankheiten
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
HUE061852T2 (hu) Dobezilsavat tartalmazó szemészeti topikális kompozíció a szem hátsó szegmense betegségeinek kezelésére
PH12021550372A1 (en) The use of alpha-2-adrenergic receptor agonists for improving vision
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.